安旭生物（688075）披露2025年度业绩快报公告，2月27日股价下跌0.18%

Core Viewpoint - Anxu Bio's 2025 annual performance report indicates a significant decline in revenue and profits, primarily due to increased tariffs from the U.S., rising operating costs, and foreign exchange losses [1] Financial Performance - Total operating revenue for 2025 was 453,575,110.94 yuan, a year-on-year decrease of 16.11% [1] - Operating profit was 69,056,267.09 yuan, down 66.73% year-on-year [1] - Net profit attributable to shareholders was 73,382,112.04 yuan, reflecting a 61.84% decline compared to the previous year [1] Asset and Equity Status - Total assets at the end of the reporting period were 5,612,123,002.48 yuan, a decrease of 2.72% from the end of the previous year [1] - Equity attributable to shareholders was 5,170,052,841.50 yuan, down 0.64% from the end of the previous year [1]